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Abstract:  Gene inactivation by promoter hypermethylation is a common occurrence in the development of
various human cancers including oral cancer. Previous evidences observed that DNA methylation play a vital
role in the carcinogenesis of oral cancer. The aim of this study was to analyze methylation status and protein
expression of RRM2 in oral cancer. Archival tissues of oral cancer and healthy mucosa tissues were retrieved
for the study. The methylation status of RRM2 was examined by methylation specific polymerase chain reaction
and its protein expression was measured by immunohistochemistry. In the present study, frequency of aberrant
methylation of RRM2 was 80% (n=32) in tumour tissues, whereas such methylation status was negatively
detected in normal mucosa. In addition, 20 % (n=8) for RRM2 immunoreactivity was revealed in tumour tissues.
In tumour tissues, RRM2 promoter hypermethylation was frequently associated with its reduced protein
expression. Thus, epigenetic inactivation of RRM2 through promoter hypermethylation may be important in
the oral cancer progression and assessment of RRM2 methylation status in oral cancer may become a potential
biomarker for early detection in oral cancer.
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INTRODUCTION involved in DNA synthesis, cell growth and drug
Ribonucleotide reductase (RR) is constitutively alteration in RRM2 expression leads to tumour initiation
present in all dividing cells, which is involved in and progression, suggesting its possible role as
ribonucleotides to deoxyribonucleotides conversion, as prognostic factor and therapeutic target for cancer [3].
a rate limiting step of de novo deoxyribonucleotide Therefore, this study highlighted the methylation status
triphosphate (dNTP) biosynthesis [1]. RR  consists of and protein expression of RRM2 and clinically relevant
two subunits of R1 and R2 have their specific role in aspects of the expression and functions of RRM2 in oral
nucleotide biosynthesis. The larger subunit, R1 plays a cancer were retrieved.
role as catalytic and regulation site of gene expression, In year of 2008, Xu et al. [4] reported RRM2
whereas, smaller R2 subunit contains two iron moieties overexpression results in high mutational rate in lung
which are used for free radicals generation in reduction of cancer with association of largest tumour size, greatest
hydroxyl group of the ribose sugar [2]. tumour multiplicity and higher grade of pathology stage.
In several evidences it was shown that They also observed that the free radical of normal product
Ribonucleotide Reductase subunit M2 (RRM2) is of  RRM2  activity  may  result  in  G  to  T  transversion.
resistance of cancer cells. It was also revealed that
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A study reported that RRM2 inhibition can inhibit cancer SUBJECTS AND METHODS: Study population: Four healthy
cell growth and overcomes drug resistance, where the mucosal tissues surrounding impacted teeth and 40 OSCC
novel RNR inhibitor, COH29 had inhibited RRM2 tissues  of   archived   specimens   were   subjected  in  the
expression in human cancer cell lines, ovarian cancer and methylation specific polymerase chain reaction (MSPCR)
leukaemia [5]. and immunohistochemistry (IHC) assays. The selected
Oral cancer is the tenth most common malignancy normal tissues were from healthy subjects who are non-
with a worldwide incidence of 275,000 cases reported smokers, non-alcoholics, non-betel quid chewers, no
annually, two thirds of these cases occur in developing clinical oral lesions and free from other diseases. All
countries [6, 7]. Oral cancer remains a significant burden OSCC patients were new cases and had not cancer
worldwide in terms of treating or curing the patients. therapy treated before. The tissue samples and relevant
Despite desirable outcomes in early diagnosis and clinical data were obtained from the Malaysia Oral Cancer
advance treatment, most cases are still detected in late Database and Tissue Bank System (MOCDTBS)
stages of disease with 5-year survival rate of less than coordinated by the Oral Cancer Research and
50%  with  contributing  to  the  high  cancer  morbidity Coordinating Centre (OCRCC) of University of Malaya.
and mortality [8]. In addition, oral carcinogenesis is a This present study had obtained ethic reference no: DF
complex biological process, which accurate molecular OP1101/0049 (L) from the Medical Ethics Committee of the
mechanisms regarding its pathogenesis remain to be Faculty of Dentistry, University of Malaya.
understood. Thus of greatest advantage in molecular
research  would  be  the significant biomarkers that DNA Extraction: DNA extraction protocol using
capable of identification in the early events of QIAamp® DNA Extraction Mini Kit (Qiagen, Germany)
carcinogenesis. based on the manufacturer’s procedure was carried out.
In addition to genetic changes in molecular The quality and purity of the genomic DNA were
mechanisms, any epigenetic alteration such as DNA analysed by NanoDrop Spectrophotometer ND-1000
methylation, histone modifications, chromatin structure, (NanoDrop Technologies) and the quality of DNA was
microRNA and other genomic functions may make an checked by 1% agarose gel electrophoresis. 
individual  susceptible  to  developing  cancer  [9, 10].
Hyper-methylation of promoter CpG islands has been Bisulfite-Converted    DNA:    EpiTect     bisulfite   kit
recognized  as  one  of  the  most  important  variations in (Cat. No. 59104, Qiagen, CA) was used for bisulfite-
the  progression  of  the cancer [11]. Growing evidence converted DNA extraction according the manufacturer’s
data points to the critical role of CpG island protocol. The DNA products were qualified by NanoDrop
hypermethylation in genes implicated in apoptosis, cell Spectrophotometer ND-1000 (NanoDrop Technologies)
cycle regulation and cellular differentiation in various with an extinction coefficient for single stranded DNA of
types of cancer [10, 12]. In respect to oral cancer 33ng-cm/µl. The purified bisulfite-converted DNA was
development, current studies showed that epigenetic ready for down streamed analysis.
silencing of cancer-linked genes through DNA
methylation plays a significant role [13_C14]. In the Methylation-Specific Polymerase Chain Reaction
genomes of mammals, methylation takes place at CpG (MSPCR): The procedure was conducted according to
islands that are located in the promoter region of the manufacturer’s instructions (EpiTect MSP Kit, Qiagen,
approximately half of the genes. These are heritable CA). The bisulfide-converted DNA of normal and OSCC
throughout mitosis and are copied to the new strand by cases were subjected to PCR machine (Eppendorf master
DNA methylatransferase-1 during DNA replication [15]. cycler, Germany). Thermo cycling conditions were carried
Although the accurate function of DNA methylation in out using the following settings: Initial activation step:
oral squamous cell carcinoma (OSCC) is not fully 95°C for 10 minutes; 35 cycles in the denaturation step:
understood. Overall, DNA methylation represses 94°C for 15 seconds; annealing step: Tm of primer 54°C;
transcription and loss of methylation restores gene extension step: 72°C for 30 seconds; and final extension:
activation [16]. Thus, methylation status of RRM2gene 72°C for 10 minutes. Parallel with each reaction,
and its protein expression in patients with OSCC were unmethylated and methylated DNA controls  (Catalog
revealed in this study. NO. D5014, ZYMO, Orange, CA, USA) were run as
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negative and  positive  controls  respectively.  MSPCR methylation status of MSPCR. The percentage of median
was  performed using the primer sequences of RRM2
listed  below:  The  methylated  reaction   primer
sequences were 5'TCGTTTTGTTTTGGTTGTTC3' (sense)
and       5'GCGAACTCACCGTATTCTC3'       (antisense),
For  the  unmethylated  reaction, the primer sequences
were 5'TAGTTGTTTTGTTTTGGTTGTTT3' (sense) and
5'CCCACAAACTCACCATATTCTC 3' (antisense) and
the produce size was 115 bp. Five microliters of each
MSPCR products were placed on 1% agarose gels and
were visualized by ethidium bromide staining and gel
image was captured under Olympus BX 61 fluorescence
microscope.
Immunohistochemical Staining: Normal oral mucosa and
OSCC were used for the immunohistochemical detection
of RRM2 protein. The confirmed OSCC cases were used
as positive control on each IHC run. The protocol was
performed with DAKO REAL EnVision Detection System
(Dako, USA, Carpinteria, CA)
The primary antibodies applied for
immunohistochemical analysis was mouse monoclonal
antibody  to  human  RRM2  (dilution  factor  1:450)  with
30 min. of incubation time.After process of
deparaffinization and rehydration, slides were heated in a
microwave for 5mins in 10 mM citrate buffer (pH 6.0) for
antigen retrieval, followed by rinsing in Tris phosphate
buffer (TBS) solution. After quenching endogenous
peroxidase activity in 3% hydrogen peroxide in methanol
for 5 min., the sections were rinsed in TBS. Later, the
sections were incubated with mouse anti-human RRM2
monoclonal antibody (Dako, Glostrup, Denmark) at a
dilution of 1:450 for 30 min. at room temperature in a
humidified chamber. After that, slides were incubated with
10% horseradish-peroxidase complex for 30 min., followed
by  10  min.  incubation  of diaminobenzidine substrate.
The slides were then lightly counterstained with
hematoxylin, dehydrated in a graded ethanol series,
cleaned in xylene and mounted. To measure RRM2 protein
expression, a Quantitative scoring method was applied
using digital image analysis. Data are expressed as the
presence of positive cells in percentages (positively
brown stained divided by tumour area). The evaluation
was done qualitatively by taking the definite positive
brown staining at the specific cellular location of each
protein [17]. In the study, RRM2 revealed cytoplasmic
staining of the cells. IHC staining scoring were examined
by  an    evaluator    without    prior    knowledge    of   the
value of RRM2 immunostaining demonstrated in tumour
tissues was 20.0%. Protein expression with a value of
more than 20.0% as a median percentage was considered
to be overexpressed.
Statistical Analysis: Data obtained from MSPCR analysis
was analyzed using descriptive analysis. The quantitative
data obtained as continuous abnormally distributed
variables were presented as median (interquartile) for
percentage of protein expressions. Association of gene
hypermethylation and protein expression was conducted
by Chi-square and Fisher’s exact tests. All the obtained
data were analysed by SPSS software, version 21 (SPSS,
Chicago, USA). Statistical significance was  accepted  at
p <0.05. 
RESULTS
Study Population: Fixed formalin paraffin embedded
(FFPE) tissue samples of 40 OSCC and 4 normal tissues
were collected over a time period of five years from 2005
to 2010 for the assay.
Methylation-Specific Polymerase Chain Reaction:
Methylation-specific polymerase chain reaction was
applied for RRM2 methylation status. The methylation
status and  frequency  of  BCL2  hypermethylation
revealed 80% (n=32). Whereas, RRM2 shown 20% (n=8)
for unmethylation status. Representative agarose gel
image is shown in Fig. 1. 
Immunohistochemical Analysis: To detect the protein
expression levels of RRM2, IHC analysis was performed
on normal oral mucosa and OSCC tissues. Negative
immunostaining of OSCC tissue was observed in negative
control sections of RRM2 (Fig. 2). RRM2 demonstrated
cytoplasmic immunostaining (Fig 3) in OSCC tissue. A low
percentage of cases of positive immunostaining was
demonstrated in tumour tissues for RRM2 with 22.5%
(9/40).
Association Between Gene Methylation Levels and
Protein Expressions of RRM2: The Chi-square and
Fisher’s exact tests were conducted to investigate the
association between gene hypermethylation and protein
expressions. The results showed an association between
gene hypermethylation level with protein expression of
RRM2 (p=0.001).
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Fig. 1: Representative agarose gel electrophoretic image of methylation status for gene RRM2 in methylation control and
tumour samples. DKO represents methylation control; M represents methylated alleles and U represents
unmethylated alleles. Lane 1: ladder marker of 50 bp. Lanes 2 and 3: universal methylated (DKO M) and
unmethylated control (DKO U). Lanes 4-15 represent methylation status of tumour samples. Samples no. 27, 28,
29, 30, 31 and 32 show methylated status.
Fig. 2: Formalin-fixed paraffin-embedded section of Fig. 3: Section of representative Oral Squamous Cell
representative Oral Squamous Cell Carcinoma Carcinoma tissues was stained with the antibodies
tissues was stained with the antibodies against against RRM2. Positive RRM2 cytoplasmic
RRM2. Negative RRM2 cytoplasmic staining (with staining (with red arrow) was detected in the
red arrow) shows in the tumour cells of the tumour cells (40X magnification).
negative control section (40X magnification).
DISCUSSIONS chemotherapeutic development [20]. Methylation of CpG
Ribonucleotide  reductase  small subunit M2 (RRM2) direct sequencing of bisulphate-modified DNA in primary
(chromosome 2p25.1) is the main component in renal cell carcinoma [21]. However, Hsu et al. [22] has
modulating enzymatic activity of RR, which is composed correlated its overexpression with tumour malignancy and
of RRM1 and RRM2. RRM1/RRM2 complex is the major progression in the early stages of lung cancer. Rahman et
source of deoxynucleoside triphosphates for DNA al. [23] also observed that RRM2 regulates BCL2 protein
replication during S phases [18]. It is a rate-limiting stability. The RRM2 gene suppression leads to increased
enzyme in DNA synthesis and thus plays a pivotal role in Bcl-2 degradation in head and neck and lung cancer,
cell growth. Increased RR activity has been shown by where RRM2 represses expression of the antiapoptotic
increasing DNA synthesis rate to serve the proliferative protein BCL2 resulting in induction of mitochondria-
activity of cancer cells. Thus, aberration of the RR is mediated intrinsic apoptosis. The repression effect of
dramatically  associated with malignant transformation RRM2 on BCL2 was observed in our unpublished data,
and  tumour  cell  growth  [19].  These  important  roles where BCL2 demonstrated 47.3% negativity in protein
have made RRM2 to be an attractive target for expression.  In  addition,  Zhang  et  al.   [24]   found  that
promoter regions of RRM2 was rare, when analysed by
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RRM2 is involved in tumour angiogenesis and growth OSCC, as promoter hypermethylation is an epigenetic
through regulation of the expression of antiangiogenic
thrombospondin-1 and proangiogenic vascular
endothelial growth factor.
RRM2, the DNA damage repair-related nucleotide
metabolism enzyme was predominantly activated in
pathways of dCTP/dUTP metabolism, dATP/dITP
metabolism and ATP/ITP metabolism as observed in the
study [25]. RR was a catalyst in the conversion of
ribonucleotides to 2'-deoxyribonucleotides which are the
precursors for DNA synthesis and repair. Endogenous
ribonucleotides and deoxyribonucleotides are essential
metabolites that play a critical role in cell function and
determination of their levels is of fundamental importance
in understanding key cellular processes involved in
energy metabolism and molecular as well as biochemical
signalling pathways [26]. An increase of RRs activity was
observed in transforming tumour cells as the DNA
synthesis rate has increased to serve the proliferative
activities of tumour cells. Thus, aberration of the RR is
dramatically associated with malignant transformation and
tumour cell growth [27]. These important facts have made
the RRM2 gene to become an attractive target for
chemotherapeutic treatment.
A protein expression of the RRM2 was examined by
IHC. The protein expression was 100% in normal mucosa
tissues in this study. In the tumour tissues, the IHC
results revealed a low immunostaining frequency in
RRM2. Xie et al. [28] revealed that RRM2 protein
expression does not show any prognostic value even
though it was associated with pancreatic adenocarcinoma.
The fact reflected that protein expression of RRM2 is
observed previously in other cancers as in our OSCC
cases. Thus RRM2 protein expression may be used as
diagnostic and prognostic biomarkers for OSCC
identification.
In this study, there was an association observed
between gene hypermethylation levels and protein
expression of RRM2 (P=0.001). Few studies reported that
the gene hypermethylation was significantly associated
with decreased protein expression in various carcinomas
such as ovarian cancer [29] and gastric cancer [30]. Similar
finding was reported in the present study. In addition, Xie
et al. [28] showed that RRM2 protein expression does not
show any prognostic value even though it was associated
with pancreatic adenocarcinoma. The observed inverse
correlations of the hypermethylation level of RRM2 with
their protein expression was evident in OSCC samples of
this study, suggesting that the protein expressions of
RRM2  was   silenced   by  promoter  hypermethylation  in
change which acts as one of the pathways that leads to
oral carcinogenesis [13]. However, Xu et al. [31] stated
that no inverse relationship was observed between
methylation statuses with expression level. This means no
statistically significant association between the gene
hypermethylation levels with protein expression and this
might be attributed to small tumour sample size and also
type of samples selection. This may also be explained by
the multiplicity of molecular mechanisms regulating gene
expression by many other mechanisms including histone
and MicroRNA modifications as these modifications are
known to impact the transcription regulation [32, 33]. To
the best of my knowledge, presently there are no other
OSCC studies conducted on the association of RRM2
hypermethylation with the protein expression.
CONCLUSIONS
In summary, the potential signature candidate of
RRM2 in OSCC is revealed for cancer identification and
prognostication purposes. Protein expression of RRM2
gene was reduced by their promoter hypermethylation in
OSCC, as promoter hypermethylation is the predominant
mechanism in RRM2 deregulation, which seems to play an
important role in oral carcinogenesis. The inverse
correlation between gene hypermethylation and protein
expression of RRM2 in the study suggests that the
hypermethylation mechanism is an important event in
silencing expression RRM2 in the OSCC cases.
Furthermore, protein expression of RRM2 is newly
explored in the OSCC cases, which may encourage deeper
molecular understanding of OSCC progression. Hence,
this biomarker can become a helpful tool for OSCC
prognostication and diagnosis. Last but not least,
integrated available clinical data for discovering novel
prognostic marker of RRM2 may indicate poor prognosis
of OSCC as patient’s age increase.
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